brightlight schreef op 28 januari 2020 22:38:
Great posts FL, Gijpie, MB,
Despite me being 'on vacation' I would like to share a small thing which I just learned. I always wondered how it could be that analysts attributed the biggest part of cartridge growth in H2 to the U.S. market, this market being RUO after all (which I thought should result in a lower cartridge usage per console). Apparently there is such a thing as "off label use" meaning that labs (at their own discretion) can use RUO cartridges also for normal day to day usage on patients. So apparently there should not be too much of a difference in usage of RUO versus fully approved cartridges. This bodes well for the entry into the Japanese and Chinese markets. Maybe FL can better judge the impact of this on the U.S. markets.
BL